ALKERMES | ALKS - Market Capitalization


ALKERMES reported $8.55B in Market Capitalization this June of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 384.69B 19.14B Mar/2026
Acadia Pharmaceuticals USD 3.8B 724M Mar/2026
ALKERMES USD 5.88B 1.26B Mar/2026
Amgen USD 189.89B 13.64B Mar/2026
Biogen USD 26.9B 1.09B Mar/2026
BioMarin Pharmaceutical USD 10.86B 553M Mar/2026
Bristol-Myers Squibb USD 123.83B 14.02B Mar/2026
Coherus Biosciences USD 172M 19M Dec/2025
Eli Lilly USD 869.02B 146.97B Mar/2026
Gilead Sciences USD 172.99B 20.71B Mar/2026
Heron Therapeutics USD 238M 7M Dec/2025
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
J&J USD 579.15B 78.91B Mar/2026
Malin Corporation EUR 142.92M 19.65M Feb/2026
Merck USD 297.1B 35.84B Mar/2026
Nektar Therapeutics USD 11.91B 11.05B Jun/2026
Neurocrine Biosciences USD 13.25B 890M Mar/2026
Otsuka Holdings JPY 5.98T 1.16T Mar/2026
Ovoca Bio EUR 6.12M 4.93M Apr/2026
Pfizer USD 153.81B 12.24B Mar/2026
Regeneron Pharmaceuticals USD 81.68B 560M Mar/2026
Vertex Pharmaceuticals USD 113.58B 1.44B Mar/2026